These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 28615452)
21. Targeting the HER-kinase axis in cancer. Gross ME; Shazer RL; Agus DB Semin Oncol; 2004 Feb; 31(1 Suppl 3):9-20. PubMed ID: 15052539 [TBL] [Abstract][Full Text] [Related]
22. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer. Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic. Banappagari S; Corti M; Pincus S; Satyanarayanajois S J Biomol Struct Dyn; 2012; 30(5):594-606. PubMed ID: 22731912 [TBL] [Abstract][Full Text] [Related]
24. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Sheng Q; Liu J Br J Cancer; 2011 Apr; 104(8):1241-5. PubMed ID: 21364581 [TBL] [Abstract][Full Text] [Related]
25. The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner. Sak MM; Breen K; Rønning SB; Pedersen NM; Bertelsen V; Stang E; Madshus IH Carcinogenesis; 2012 May; 33(5):1031-9. PubMed ID: 22436610 [TBL] [Abstract][Full Text] [Related]
26. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817 [TBL] [Abstract][Full Text] [Related]
27. Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1). Xi R; Pun IH; Menezes SV; Fouani L; Kalinowski DS; Huang ML; Zhang X; Richardson DR; Kovacevic Z Mol Pharmacol; 2017 May; 91(5):499-517. PubMed ID: 28275050 [TBL] [Abstract][Full Text] [Related]
28. The Oncogenic Signaling Disruptor, NDRG1: Molecular and Cellular Mechanisms of Activity. Chekmarev J; Azad MG; Richardson DR Cells; 2021 Sep; 10(9):. PubMed ID: 34572031 [TBL] [Abstract][Full Text] [Related]
29. Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling. Wangpu X; Lu J; Xi R; Yue F; Sahni S; Park KC; Menezes S; Huang ML; Zheng M; Kovacevic Z; Richardson DR Mol Pharmacol; 2016 May; 89(5):521-40. PubMed ID: 26895766 [TBL] [Abstract][Full Text] [Related]
30. Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations. Walsh AM; Lazzara MJ Integr Biol (Camb); 2014 Mar; 6(3):312-23. PubMed ID: 24445374 [TBL] [Abstract][Full Text] [Related]
32. NDRG1 functions in LDL receptor trafficking by regulating endosomal recycling and degradation. Pietiäinen V; Vassilev B; Blom T; Wang W; Nelson J; Bittman R; Bäck N; Zelcer N; Ikonen E J Cell Sci; 2013 Sep; 126(Pt 17):3961-71. PubMed ID: 23813961 [TBL] [Abstract][Full Text] [Related]
33. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. Hendriks BS; Opresko LK; Wiley HS; Lauffenburger D J Biol Chem; 2003 Jun; 278(26):23343-51. PubMed ID: 12686539 [TBL] [Abstract][Full Text] [Related]
34. Expression of the ERBB Family of Ligands and Receptors in Gastric Cancer. Byeon SJ; Lee HS; Kim MA; Lee BL; Kim WH Pathobiology; 2017; 84(4):210-217. PubMed ID: 28399526 [TBL] [Abstract][Full Text] [Related]
35. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells. Kim J; Lee J; Kim C; Choi J; Kim A Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908 [TBL] [Abstract][Full Text] [Related]
37. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. Xu X; Sutak R; Richardson DR Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550 [TBL] [Abstract][Full Text] [Related]
38. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185 [TBL] [Abstract][Full Text] [Related]
39. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Yen L; Benlimame N; Nie ZR; Xiao D; Wang T; Al Moustafa AE; Esumi H; Milanini J; Hynes NE; Pages G; Alaoui-Jamali MA Mol Biol Cell; 2002 Nov; 13(11):4029-44. PubMed ID: 12429844 [TBL] [Abstract][Full Text] [Related]
40. The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR. Zhou X; Agazie YM Cell Signal; 2012 Jan; 24(1):140-50. PubMed ID: 21911055 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]